HighTower Advisors’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,200
Closed -$8.65K 3702
2025
Q3
$8.65K Sell
1,200
-1,102
-48% -$8.11K ﹤0.01% 3706
2025
Q2
$22.9K Buy
2,302
+500
+28% +$5.28K ﹤0.01% 3608
2025
Q1
$17.1K Buy
1,802
+1,600
+792% +$22.2K ﹤0.01% 3528
2024
Q4
$2.79K Sell
202
-104
-34% -$1.82K ﹤0.01% 3663
2024
Q3
$5K Sell
306
-5,995
-95% -$29.7K ﹤0.01% 3588
2024
Q2
$30K Buy
6,301
+5,400
+599% +$30.1K ﹤0.01% 3366
2024
Q1
$6K Buy
+901
New +$4.36K ﹤0.01% 3427
2023
Q1
Sell
-19,885
Closed -$76K 3444
2022
Q4
$76K Buy
19,885
+3,001
+18% +$14.3K ﹤0.01% 2971
2022
Q3
$102K Sell
16,884
-3,599
-18% -$18.4K ﹤0.01% 2765
2022
Q2
$72K Sell
20,483
-1,400
-6% -$4.97K ﹤0.01% 2852
2022
Q1
$75K Buy
+21,883
New +$86.3K ﹤0.01% 3032
2021
Q4
Sell
-53,960
Closed -$215K 3313
2021
Q3
$215K Buy
53,960
+47,660
+757% +$217K ﹤0.01% 2654
2021
Q2
$33K Sell
6,300
-6,000
-49% -$25.4K ﹤0.01% 2924
2021
Q1
$57K Sell
12,300
-4,000
-25% -$23K ﹤0.01% 2815
2020
Q4
$56K Buy
16,300
+6,000
+58% +$26K ﹤0.01% 2399
2020
Q3
$55K Sell
10,300
-2,700
-21% -$15.7K ﹤0.01% 2298
2020
Q2
$59K Buy
+13,000
New +$56.7K ﹤0.01% 2188

Other funds holding CAPR

HighTower Advisors's CAPR Position: Q4 2025 in Review

HighTower Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 1,200 shares — an estimated $8.65K sold.

HighTower Advisors first reported a position in CAPR in Q2 2020 and held it in 17 quarters. The position peaked at $215K in Q3 2021. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • HighTower Advisors reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HighTower Advisors sold 1,200 Capricor Therapeutics shares in Q4 2025, an estimated $8.65K.
  • HighTower Advisors first reported a position in Capricor Therapeutics in Q2 2020 and held it in 17 quarters.
  • HighTower Advisors's Capricor Therapeutics position peaked at $215K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.